Traders Sell Johnson & Johnson (JNJ) on Strength (JNJ)

Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Wednesday. $186.17 million flowed into the stock on the tick-up and $300.65 million flowed out of the stock on the tick-down, for a money net flow of $114.48 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 4th highest net out-flow for the day. Johnson & Johnson traded up $2.75 for the day and closed at $136.65

JNJ has been the subject of several research analyst reports. BidaskClub raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $128.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 15th. Atlantic Securities downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target for the company. in a research note on Friday, July 21st. Jefferies Group LLC reaffirmed a “hold” rating and issued a $145.00 price target (up from $140.00) on shares of Johnson & Johnson in a research note on Friday, July 14th. Finally, Citigroup Inc. initiated coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They issued a “neutral” rating and a $140.00 price target for the company. Five investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and an average price target of $136.02.

The firm has a market capitalization of $366.77 billion, a P/E ratio of 23.12 and a beta of 0.78. The company has a 50 day moving average of $132.27 and a 200-day moving average of $130.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the business earned $1.74 EPS. On average, analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were paid a $0.84 dividend. The ex-dividend date was Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.46%. Johnson & Johnson’s payout ratio is 56.76%.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. BlackRock Inc. increased its stake in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. State Street Corp increased its stake in Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after purchasing an additional 6,656,371 shares in the last quarter. FMR LLC increased its stake in Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after purchasing an additional 1,509,745 shares in the last quarter. Finally, Capital World Investors increased its stake in Johnson & Johnson by 4.1% during the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after purchasing an additional 1,050,000 shares in the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2017/10/12/traders-sell-johnson-johnson-jnj-on-strength-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply